Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Leukemia, Myeloid, Acute 97Myelodysplastic Syndromes 20Leukemia, Myelomonocytic, Chronic 10Recurrence 8Leukemia 8Neoplasm, Residual 6Hematologic Neoplasms 6Myeloproliferative Disorders 5Lymphoma, T-Cell, Peripheral 5Leukemia, Biphenotypic, Acute 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Monocytic, Acute 3Anemia, Refractory, with Excess of Blasts 3Myeloid Malignancy 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2GATA2 Deficiency 2Breast Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Pathologic Complete Response 1

Interventions

Azacitidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Myeloid Malignancy × Azacitidine × Clear all
NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Henry Ford Health System

Phase 2 Recruiting
43 enrolled

Myeloid Malignancy

NCT07011186 2025-06-08

A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
138 enrolled

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡